Investigational drug · Phase 2
SPI-62
Also called: clofutriben, ASP3662
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Cortisol Excess, Type 2 Diabetes, Polymyalgia Rheumatica.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
1 still active
All registered trials
6
Any phase or sponsor naming "SPI-62"
First trial start
2022
Jul 22, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SPI-62", any sponsor or status.
Conditions studied
As listed on its trial records.
- Cortisol Excess
- Type 2 Diabetes
- Polymyalgia Rheumatica
- Cushing's Syndrome I
- Cushing Disease Due to Increased ACTH Secretion
- Cortisol; Hypersecretion
- Cortisol Overproduction
- Ectopic ACTH Secretion
Approved drugs for the same conditions: Type 2 diabetes · Cushing's syndrome · Cardiovascular and metabolic · Rare and genetic disease · Endocrinology and women's health
Largest trials
Live from ClinicalTrials.gov: studies naming "SPI-62" as an intervention, largest first.
- Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)Pivotal-lookingRecruiting
Sparrow PharmaceuticalsIndustry
NCT07296484 · 1,500 participants (planned) · Start Nov 29, 2025 · Primary completion Dec 31, 2027
Drug: clofutriben; Placebo · For: Type 2 Diabetes; Cortisol Excess
Sites: Chandler, Arizona; Tucson, Arizona; Fountain Valley, California · 61 sites in all
Sparrow PharmaceuticalsIndustry
NCT05436652 · 66 participants · Start Jul 22, 2022 · Primary completion Apr 25, 2025
Drug: SPI-62; SPI-62 matched placebo and 3 more · For: Polymyalgia Rheumatica
Sites: Berlin, Germany; Erlangen, Germany; Hamburg, Germany · 10 sites in all
Sparrow PharmaceuticalsIndustry
NCT05436639 · 30 participants · Start Jul 1, 2023 · Primary completion Dec 1, 2024
Drug: SPI-62 dose · For: Autonomous Cortisol Secretion (ACS); ACTH-Independent Cushing Syndrome; ACTH-Independent Adrenal Cushing Syndrome, Somatic
Sites: Rochester, Minnesota; Columbus, Ohio; Brasov, Romania · 5 sites in all
Sparrow PharmaceuticalsIndustry
NCT05307328 · 26 participants · Start Sep 1, 2022 · Primary completion Aug 1, 2025
Drug: SPI-62; Placebo · For: Cushing's Syndrome I; Cushing Disease Due to Increased ACTH Secretion; Cortisol Excess and 3 more
Sites: Phoenix, Arizona; Fort Myers, Florida; Rochester, Minnesota · 12 sites in all
- A Study to Assess 11 Beta-hydroxysteroid Dehydrogenase Type 1 Inhibition in Adipose Tissue by SPI-62Completed
Sparrow PharmaceuticalsIndustry
NCT05409027 · 12 participants · Start Jul 23, 2021 · Primary completion Mar 10, 2022
Drug: SPI-62; Cortisone-d8 · For: Type 2 Diabetes Mellitus in Obese; Obesity; Type2Diabetes
Sites: Chula Vista, California
- A Trial of Prednisolone in Combination With SPI-62 in Participants With Polymyalgia Rheumatica (PMR)Terminated
Sparrow PharmaceuticalsIndustry
NCT06281236 · 1 participants · Start Feb 22, 2022 · Primary completion Mar 25, 2025
Drug: Prednisolone; SPI-62 · For: Polymyalgia Rheumatica
Sites: Berlin, Germany; Hanover, Germany; Mainz, Germany · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- More is less: Glucocorticoid-sparing agents in polymyalgia rheumatica.
Palmowski A, Buttgereit F, Strangfeld A, et al. · Ther Adv Musculoskelet Dis 2026
- Small-Molecule Strategies for Polymyalgia Rheumatica and Giant Cell Arteritis in Older Adults.
Kurdybacha J, Kravets O, Lekston N, et al. · Molecules 2026
- Effects of clofutriben, a selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, on the efficacy and toxicity of prednisolone in patients with polymyalgia rheumatica: a single-blind controlled trial with sequential cohorts.
Buttgereit F, Everding A, Andreica I, et al. · Ann Rheum Dis 2026
- Human Adipose Tissue 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibition Without Tachyphylaxis by Clofutriben, a Pseudo-Irreversible Enzyme Inhibitor.
An G, Gutierrez JA, Abad-Zapatero C, et al. · Clin Transl Sci 2025
- Advances in pharmacological treatment of Cushing's disease.
Chai J, Tang Y, Liu Y, et al. · Zhong Nan Da Xue Xue Bao Yi Xue Ban 2024
- Investigational agents for polymyalgia rheumatica treatment: assessing the critical needs for future development.
Iorio L, Padoan R, Bond M, et al. · Expert Opin Investig Drugs 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.